Rapport Therapeutics, Inc. (NASDAQ:RAPP)
| Market Cap | 2.09B+88.0% |
| Revenue (ttm) | 20.00M |
| Net Income | -137.16M-55.3% |
| EPS | -3.04-21.6% |
| Shares Out | 47.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 251,786 |
| Open | 44.21 |
| Previous Close | 43.46 |
| Day's Range | 43.08 - 44.22 |
| 52-Week Range | 22.73 - 52.93 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 62.80(+43.97%) |
| Earnings Date | Nov 5, 2026 |
About RAPP
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$RAPP stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RAPP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RAPP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RAPP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RAPP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RAPP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RAPP
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $40.44M |
| IWMiShares Russell 2000 ETF | $34.19M |
| VXFVanguard Extended Market ETF | $13.60M |
| IWOiShares Russell 2000 Growth ETF | $11.87M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $9.59M |
| IBBiShares Biotechnology ETF | $9.46M |
Estimated from each fund’s disclosed top holdings × AUM
RAPP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RAPP’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score